Adalimumab biosimilar (HEC Pharma)

阿达木单抗生物类似药（东阳光）

Report date: 2022/03/14 10:33:41

Base Information

Drug NameAdalimumab biosimilar (HEC Pharma)
Drug Alias Name重组抗TNF-α全人源单克隆抗体（广东东阳光）Recombinant human anti-TNFα monoclonal antibody重组抗TNFα全人源单抗（广东东阳光）
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesGuangdong Dongyangguang Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesGuangdong Dongyangguang Pharmaceutical Co LtdGuangdong Dongyang Biological Agent Co Ltd
Inactive CompaniesN/A
Active IndicationsArthritis, Rheumatoid
Inactive IndicationsN/A

Other Information

ATC CodeL04AB04
Related LinksN/A